FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 53 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Can Age Affect Response to Immune Checkpoint Inhibitors? July 6, 2018 One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... July 16, 2020 What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? June 22, 2021 EMA Recommends Granting a Marketing Authorisation for Azacitidine May 3, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Equidacent New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21...
